AGC Biologics S.p.A. is a leading global organization for the development and manufacturing of biopharmaceutical products to third parties (CDMO), in close collaboration with customers and partners, in order to improve patients' lives by bringing new biopharmaceuticals to market. The Company provides pharmaceutical development and manufacturing services for protein-based biologics and cell and gene therapies based on proteins (using microbial and mammalian systems), plasmid DNA (pDNA), viral vectors and genetically modified cells. AGC Biologics S.p.A. has operations in the United States, Europe and Asia, with cGMP compliant sites in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan. It currently employs more than 1,600 people worldwide.

AGC Biologics S.p.A. specializes in cell therapy, development and production of viral vectors (lentiviral, retroviral and adeno-associated). The facility was the first cell and gene therapy site approved in Europe for GMP manufacturing of products intended for clinical trials and commercialization.

Through the consolidated experience of its staff and its own cGMP manufacturing facilities, AGC Biologics S.p.A. is constantly committed to providing innovative solutions to its customers in order to help them achieve their goals and accelerate the timelines of their projects. The essential objective of AGC Biologics S.p.A. is to improve patients' lives by developing and improving existing technologies and introducing new effective and competitive biopharmaceuticals to the market.

AGC Biologics S.p.A. believes it has an important obligation towards all Interested Parties and the Local Communities in which it operates to guarantee excellence in environmental performance and in terms of Workers' Health and Safety. This is achieved through the establishment of an integrated management system for the Environment, Health and Safety of Workers which:

- allows for the provision of safe and healthy working conditions for the prevention of accidents and occupational diseases, at the same time aims to prevent those technical measures adopted cause risks to the health of the population or deteriorates the external environment by periodically verifying the continuing absence of risk;
- allows compliance with all laws regarding the Environment and Worker Health and Safety;
- is aimed at preventing and reducing pollution by taking the life cycle into account;
- implements appropriate actions to eliminate, if possible, the dangers to the Environment and the Health and Safety of Workers and, in case this is not possible, reduce the risks by identifying preventive measures prior to protective ones;
- establishes objectives and targets designed to demonstrate leadership in the management of the environment and the health and safety of workers, demonstrating the commitment to continuous improvement of the Integrated Environment and Safety System;
- allows to minimize waste and, secondly, favors recovery activities over disposal ones;
- uses robust procedures, training, self-assessments, periodic management reviews and monitoring systems to ensure compliance with existing and future regulations;
- promotes effective internal and external communications to promote awareness of the integrated policy and to facilitate a timely response to environmental or worker health and safety questions or concerns;
- allows the creation of a safe work culture through the consultation and participation of Workers and their Representatives;
- considers the impact of physical and psychological factors within the working environment in the health and safety planning process;

- provides employee protection through the safe design of equipment and the workplace, technical controls and procedures, training and collective and individual protective equipment;
- enables recording and takes appropriate action in the event of reported near-misses to avoid environmental impacts or injuries.

Bresso, September 1st 2023

The General Manager